[Function of STAT1 in proliferation and differentiation of human hypertrophic scar fibroblast induced by connective tissue growth factor.]

Zhonghua Yi Xue Za Zhi. 2009 Apr 28; 89(16): 1093-7Tao L, Liu JY, Li SR, Dai X, Li ZOBJECTIVE: To validate whether STAT1 paticipated in the process of CTGF-induced proliferation and differentiation of human hypertrophic scar fibroblast (hHSF) on account of past research. METHODS: To cultivate hHSF with 6 patients' hypertrophic scar specimens together. Electrophoretic mobility shift assay (EMSA) was used to verify binding ability between DNA and STAT1 with the stimulus of different concertration CTGF (0, 5, 7.5, 10, 15 ng/ml) at 45th min and the stimulus of 10 ng/ml CTGF at different phase point (0, 10, 20, 30, 45, 60, 90, and 120 min). We divided cells into CTGF group, STAT1 ASODN group. STAT1 ASODN + CTGF group. control group. And MTT was used to detect the proliferation of hHSF on days1, 2 and 3, and RT-PCR to detect alpha-smouth muscle actin mRNA to follow the differentiation. RESULTS: EMSA showed that the binding ability between STAT1 and DNA depended on the concentration of CTGF and peaked with the stimulation of 10ng/ml CTGF. And at the same time, it peaked at 45 - 60 min with 10 ng/ml CTGF. MTT showed that cell proliferation of CTGF group was much higher than that of control group (all P < 0.05). And those of STAT1 ASODN group and STAT1 ASODN + CTGF group were much lower than those of control group and CTGF group (all P < 0.05). RT-PCR showed that differentiation activation from fibroblast to myofibroblast of CTGF group, STAT1 ASODN group, STAT1 ASODN + CTGF group and control group were 0.78 +/- 0.08, 0.38 +/- 0.09, 0.76 +/- 0.10, and 0.40 +/- 0.12, respectively. Differentiation activation of STAT1 ASODN group and control group were much lower than those of CTGF group and STAT1 ASODN + CTGF group (all P < 0.05). CONCLUSION: STAT1 ASODN is important in the process of proliferation of hHSF and it blocks the stimulation of CTGF on hHSF proliferation. The above result revealed that STAT1 participates in the process of hHSF proliferation induced by connective tissue growth factor.

Simulations and experiments of the balloon dilatation of airway stenoses / Simulationen und Experimente zur Ballondilatation von Atemwegstenosen.

Biomed Tech (Berl). 2009 Jul 14; Venhaus M, Behn C, Freitag L, Zimmermann KAbstract This article investigates the mechanics of balloon dilatation in the treatment of bronchotracheal stenosis. The "scar stricture"-type stenosis examined in this paper is typically dilated manually, using a dilatation balloon. If indicated, this is followed by stent implantation. The selection of the stent with proper characteristics is performed empirically, based on personal experience and preference. In order to optimize the therapeutic outcome, however, it is necessary to match the stent with the stress-strain properties of the stenosis, which are not determined during manual balloon dilatation. The objective is to utilize models to experimentally and theoretically establish the correlation between the pressure/volume curve measured during the dilatation and the stress-strain properties of the stenosis, taking into account that during dilatation of scar strictures the balloon is only partially compressed, as it extends beyond both ends of the stenosis. Experiments are carried out using stenosis models with various extensibilities and lengths. As expected, more hardened stenosis resulted in steeper pressure/volume curves during the dilatation. On the other hand, the comparison between stenosis of equal extensibilities, but different length, showed an initially unexpected larger distension of the shorter stenosis, at equal pressure increases. This is caused by the fact that the margins of the stenosis are allowed more time to distend, compared to the central areas of the stenosis. The term "effect of margin expansion" was introduced to describe this behavior. The modeling of the dilatation process is based on the equilibrium conditions of cut-free balloon portions. The balloon/stenosis system is divided into three areas with different characteristics: (1) the proximal and distal area of the balloon outside the stenosis; (2) the area of contact between the balloon and the stenosis; and (3) the transition area between (1) and (2). Numerical simulations of the balloon dilatation confirm the conclusions from the experimental results and the theoretical considerations regarding the correlation between the pressure/volume curve of the dilatation and the stress-strain properties of the stenosis.

Topical imiquimod in conjunction with Nd:YAG laser for tattoo removal.

Lasers Med Sci. 2009 Jul 15; Elsaie ML, Nouri K, Vejjabhinanta V, Patricia Rivas M, Magaly Villafradez-Diaz L, Martins A, Rosso RThe purpose of this study is to evaluate the efficacy of tattoo removal using topical imiquimod 5% cream in conjunction with the 1,064-nm Nd:YAG laser. This procedure for tattoo removal will be compared to laser treatment alone, which is the standard for cosmetic removal of tattoos. Previous studies have linked partial tattoo removal to imiquimod application in a guinea pig model. Methods: This was a small-sized, double-blinded, placebo-controlled trial with patients with Fitzpatrick skin types I-IV (light skin) who were 18-65 years of age. The patients were required to have had two tattoos of similar age and dark blue or black in color in areas that can be covered by clothing. There were four visits in total, with laser treatment and photography being performed on the first visit. Laser settings were with 1,064-nm Nd:YAG with a 10-ns pulse, 3-mm spot size, and 4 J of energy, a standard laser used for tattoo removal. During the second visit, tattoos were randomized and chosen to receive either the laser-imiquimod treatment course or laser-vehicle cream treatment. The patients returned 1 month after the completion of cream application (week #10) and 2 months after the completion of treatment with cream (week #14) for final evaluation and photographing. Results: Three patients were enrolled in this study. All of them are Fitzpatrick skin type IV. All of the patients were compliant with the drug application and have good tolerability with only mild pruritus without changing of vascularity or pigmentation. None of the patients had ulceration or scar development during the cream application. Conclusions: imiquimod plus laser therapy demonstrated a more favorable outcome when evaluated by the investigators or subjects. The mean scores for tattoo clearance from baseline to 2 months after completion of treatment with 5% imiquimod cream versus placebo cream were 4.3 versus 2.7 as rated by investigators and 4.7 versus 2.3 as rated by subjects. No textural changes were observed after therapy and were not shown to be different between the two groups. Further large-scale studies are important in developing a role for the use of imiqumod in laser-assisted tattoo removal.

A review of published reports on neuroprotection in spinal cord injury.

Spinal Cord. 2009 Jul 14; Onose G, Anghelescu A, Muresanu DF, Padure L, Haras MA, Chendreanu CO, Onose LV, Mirea A, Ciurea AV, El Masri WS, von Wild KRStudy design:Literature review.Objectives:To review the main published current neuroprotection research trends and results in spinal cord injury (SCI).Setting:This paper is the result of a collaboration between a group of European scientists.Methods:Recent studies, especially in genetic, immune, histochemical and bio (nano)-technological fields, have provided new insight into the cellular and molecular mechanisms occurring within the central nervous system (NS), including SCIs. As a consequence, a new spectrum of therapies aiming to antagonize the 'secondary injury' pathways (that is, to provide neuroprotection) and also to repair such classically irreparable structures is emerging. We reviewed the most significant published works related to such novel, but not yet entirely validated, clinical practice therapies.Results:There have been identified many molecules, primarily expressed by heterogenous glial and neural subpopulations of cells, which are directly or indirectly critical for tissue damaging/sparing/re-growth inhibiting, angiogenesis and neural plasticity, and also various substances/energy vectors with regenerative properties, such as MAG (myelin-associated glycoprotein), Omgp (oligodendrocyte myelin glycoprotein), KDI (synthetic: Lysine-Asparagine-Isoleucine 'gamma-1 of Laminin Kainat Domain'), Nogo (Neurite outgrowth inhibitor), NgR (Nogo protein Receptor), the Rho signaling pathway (superfamily of 'Rho-dopsin gene-including neurotransmitter-receptors'), EphA4 (Ephrine), GFAP (Glial Fibrillary Acidic Protein), different subtypes of serotonergic and glutamatergic receptors, antigens, antibodies, immune modulators, adhesion molecules, scavengers, neurotrophic factors, enzymes, hormones, collagen scar inhibitors, remyelinating agents and neurogenetic/plasticity inducers, all aiming to preserve/re-establish the morphology and functional connections across the lesion site. Accordingly, modern research and experimental SCI therapies focus on several intricate, rather overlapping, therapeutic objectives and means, such as neuroprotective, neurotrophic, neurorestorative, neuroreparative, neuroregenerative, neuro(re)constructive and neurogenetic interventions.Conclusion:The first three of these therapeutical directions are generically assimilated as neuroprotective, and are synthetically presented and commented in this paper in an attempt to conceptually systematize them; thus, the aim of this article is, by emphasizing the state-of-the art in the domain, to optimize theoretical support in selecting the most effective pharmacological and physical interventions for preventing, as much as possible, paralysis, and for maximizing recovery chances after SCI.Spinal Cord advance online publication, 14 July 2009; doi:10.1038/sc.2009.52.